Objective: To evaluate the risk factors for recurrence of high-grade disease after cervical excision in women living with HIV (WLWH), with a specific interest in the role of high-risk (HR-) HPV positivity.

Methods: Multicentric retrospective study conducted on WLWH who underwent cervical excision between January 1987 and June 2017 in six Italian institutions. The rate of high-grade recurrence was determined. Risk factors for recurrence and HR-HPV positivity were determined with the Log-rank test and Cox proportional hazards regression models.

Results: A total of 271 WLWH were included in the final analysis. A high-grade recurrence was found in 58 (21.4%) patients. Age 41 years or more at inclusion and HR-HPV positivity during follow up were independently associated with a higher risk of disease recurrence with relative risks of 4.15 (95% confidence interval [CI] 2.01–8.58, \( P < 0.001 \)) and 5.18 (95% CI 2.12–12.67, \( P < 0.01 \)), respectively. Age 41 years or more (relative risk 1.75, 95% CI 1.01–3.04, \( P = 0.047 \)) resulted as a risk factor for HR-HPV positivity during follow up.

Conclusion: HR-HPV positivity is a risk factor for recurrence after cervical excision in WLWH. Women older than 41 years may benefit from a long-term yearly follow up. Future studies regarding HPV vaccination after treatment in WLWH may be useful, considering the protective role of the higher probability of HPV negativity in vaccinated women.

Keywords: cervical excisional procedure, cervical intraepithelial neoplasia, conization, HIV, recurrence
Human papillomavirus (HPV) infection is the most common sexually transmitted infection, with over 300 million infected women globally. Risk factors for acquiring HPV infection include multiple sexual partners, immunodeficiency status, early sexual debut, parity, use of contraceptives, and smoking. Compared with the general female population, women living with HIV (WLWH) have a higher prevalence of high-risk HPV (HR-HPV) infection, HR-HPV persistent infection, higher risk of cervical intraepithelial neoplasia (CIN) lesions, and higher incidence of cervical cancer. The presence of HIV and related immunosuppression significantly affects the natural history of HR-HPV infection, increasing the susceptibility to acquiring HR-HPV, reducing the rate of clearance, and favoring both the reactivation of latent infection and the persistence of HR-HPV infection. Severe immunosuppression, as reflected by low CD4+ T-cell count or increased HIV loads, has been consistently associated with the risk of HR-HPV infection itself and with the risk of preinvasive and invasive cervical lesions. Highly active antiretroviral therapy (HAART), together with the associated immune reconstitution, seems to improve the control of HR-HPV infection and disease progression.

To date, because primary prevention with HPV vaccination in WLWH, although promising, still does not have strong scientific validation and further studies are undoubtedly necessary, cervical cancer prevention in WLWH is mainly based on secondary prevention, with early diagnosis and treatment of high-grade CIN (CIN 2/3). Surgical cervical excision (i.e. loop electrosurgical excision procedure, laser conization, or cold-knife conization) is the recommended procedure in the case of CIN 2/3. Although the surgical treatment of cervical cancer precursors is highly effective in immunocompetent women, with eradication in about 90% of cases, a lower efficacy has been reported in WLWH, in whom high rates of persistent and recurrent disease have been found in several studies. For this reason, a long-term follow up is necessary for WLWH subjected to cervical excision for intraepithelial neoplasia. However, there is currently no consensus as to what the follow-up method after cervical excision in WLWH should be. Available guidelines contain recommendations ranging from the same methods of follow up as HIV-negative women to annual follow up, particularly in the case of severe immunodeficiency.

Evidence suggests that several factors may be associated with increased rates of persistent and recurrent disease after treatment, including smoking, positivity of cone margins, persistent HR-HPV infection, and immunosuppression. Persistent HR-HPV infection is gaining increasing importance in the evaluation of the recurrence risk after treatment in HIV-negative women, but evidence in this regard is scarce for WLWH. Knowing the impact of HPV infection on the risk of recurrence after treatment might also be the basis for future studies on the role of HPV vaccination after treatment in WLWH.

The aim of the present study was, therefore, to evaluate the risk factors for recurrence of high-grade lesions after cervical excision in WLWH, with a specific interest in the role of HR-HPV positivity during follow-up.
T-cell count of 200–349 cells/µl, and severe for a CD4+ T-cell count below 200 cells/µl.

The use and type of antiretroviral therapy (ART) were recorded on the basis of the medications listed in the patients’ chart. HAART was defined according to the contemporary definition of two nucleoside reverse-transcriptase inhibitors and at least one of the following: a protease inhibitor, a non-nucleoside reverse-transcriptase inhibitor, or an additional nucleoside reverse-transcriptase inhibitors. All other types of ART used before 1996 were defined as pre-HAART.

The post-treatment follow-up strategy was the following: first control with cervical cytology and colposcopy at 6 months from the procedure; after that, these patients underwent cervical cytology and colposcopy every 6 months until 24 months from treatment. After that, women underwent cervical cytology every 12 months with colposcopy in the case of abnormalities at cervical cytology. HR-HPV testing was also added after 2002, when available, at the time of treatment and at yearly intervals. Biopsies were prompted by abnormal cytology or the presence of an abnormal transformation zone at colposcopy.

Disease recurrence was defined as a histopathologic diagnosis of high-grade lesions (HSIL, CIN2/3) or worse (HSIL+) during follow up. These women were followed from the date of first follow up after treatment until the date of recurrence or until the date of the last registered follow up if no recurrence took place.

The primary outcome of the study was the rate of high-grade recurrence or cancer (HSIL+) among WLWH.

All continuous variables were tested for normality with the D’Agostino-Pearson test. Normally distributed variables were expressed as mean ± standard deviation, while skewed variables were reported as median and interquartile range (IQR). Categorical variables were reported as numbers and percentages. A Kaplan-Meier analysis at 180 months of follow up for the whole population was performed to evaluate the probability of disease recurrence.

All sociodemographic, clinical, and HIV-specific variables were evaluated as risk factors for disease recurrence with the log-rank test. Factors that were associated with recurrence were considered as covariates in a subsequent Cox proportional-hazards regression model. Risk factors for HPV-positivity during follow up were evaluated with the same methodology. A P value <0.05 was considered statistically significant. Patients with missing data were excluded and a complete case analysis was performed. Calculations were done using IBM SPSS version 27.0 (IBM Corp., Armonk, NY, USA). As this was a retrospective analysis of routinely collected data, there was no need for ethical approval. Patients signed informed consent for data collection and procedure at the time of intervention.

3 | RESULTS

During the study period, 345 WLWH underwent cervical excision in the six institutions involved. Thirty-four women with incomplete data were excluded, leaving 311 for analysis. The majority of patients (281/311, 90.4%) were white, with a mean age ± standard deviation at inclusion of 35.5 ± 7.9 years. Fourteen (4.5%) women were in menopause at the time of treatment. The reported age at first intercourse was 16 years or less in 150 (48.2%) women, and 148 (47.6%) women reported a having five or fewer partners. Tobacco use was reported by 209 (67.2%) women. One hundred and sixty (51.5%) women were nulliparous at inclusion. Regarding HIV-related characteristics, 171 (55.0%) had been infected by HIV via heterosexual contact. The median (IQR) CD4+ T-cell count at inclusion was 365 (240–500) cells/µl. According to the WHO immunologic classification, 67 (21.5%) of these women presented a severe immunodeficiency, 66 (21.2%) an advanced immunodeficiency, 86 (27.7%) a mild immunodeficiency, and 92 (29.6%) a not significant immunodeficiency. At the time of treatment, 73 (23.5%) women were not receiving ART, 81 (26.0%) were receiving mono- or dual-nucleoside reverse-transcriptase inhibitors (pre-HAART) therapy, and 157 (50.5%) were receiving HAART.

In the 165 women in whom an HR-HPV test was performed at inclusion, the result was positive in 148 (89.7%). The preoperative diagnosis was HSIL (CIN2/3) at punch-directed biopsy in 246 (79.1%) patients, high-grade cervical cytology (HSIL or atypical squamous cells, cannot rule out high-grade squamous intraepithelial lesion) in 7 (2.3%), persistent LSIL (CIN1) in 53 (17.0%), and persistent low-grade cervical cytology (LSIL or atypical squamous cells of undetermined significance) in the remaining 5 (1.6%) patients.

At the preoperative colposcopy, the squamocolumnar junction was visible in 206 (66.2%) patients, and major colposcopic changes or signs of suspected invasion were observed in 167 (53.7%).

Treatment was performed by loop electrical excision procedure in 255 (82.0%) patients, by CO2-laser in 40 (12.9%), and by cold knife in the remaining 16 (5.1%). At the histopathologic analysis of the cone specimens, the cone result was negative in 3 (1.0%) cases, LSIL (CIN1) in 23 (7.4%) patients, HSIL (CIN2) in 137 (44.1%), HSIL (CIN3) in 140 (45.0%), and invasive cancer in eight (2.5%) patients. The endocervical margin was negative in 272 (87.5%) patients.

Among the 277 WLWH diagnosed with HSIL (CIN2/3) at the cone specimen, six patients with no documented follow up were excluded, leaving 271 patients diagnosed with HSIL (CIN2/3) for the analysis of disease recurrence. Figure 1 presents the flowchart of the study population.

The median (IQR) duration of follow up was 44 (17–88) months. Among the 271 women retained in follow up, 213 (78.6%) women had no sign of recurrent disease. A recurrence of HSIL+ was found in 58 (21.4%) women. The median (IQR) time to recurrence was 18 (7–43) months. Among those patients, there were six cases (2.2%) of invasive cancer diagnosed: two at 12 months, two at 24–36 months, and two more than 60 months after treatment. The overall rate of subsequent invasive cervical cancer was 2.2% (6/271 patients). All cases of recurrence underwent a second excisional procedure.

The Kaplan-Meier analysis at 180 months of follow up showed a probability of negative follow up at 24 months of 85.5% (standard error [SE] 2.0%), at 60 months of 78.3% (SE 2.9%), at 120 months of 72.3% (SE 3.6%), and at 180 months of 63.9% (SE 5.2%).
We evaluated the influence of all sociodemographic, clinical, and HIV-specific variables as risk factors for disease recurrence with the log-rank test (Table 1). Two factors were associated with the recurrence of high-grade disease with a P value <0.05: age 41 years or more and HR-HPV positivity at follow up; those factors were considered as covariates in the subsequent Cox proportional hazards regression model. Both included factors that were significantly and independently associated with a higher risk of disease recurrence: age 41 years or more with a relative risk (RR) of 1.75 (95% confidence interval [CI] 1.01–3.04, P = 0.047) and HR-HPV positivity during follow up with an RR of 5.18 (95% CI 2.01–8.58, P < 0.001) and HR-HPV positivity during follow up as a risk factor for both short-term and long-term recurrence of cervical lesions after treatment in HIV-negative women.

This association has been evaluated less frequently in WLWH, and data are not as consistent. Indeed, whereas Massad et al. reported a hazard ratio of 2.9 in case of HPV positivity for recurrence of any grade, Lodi et al. affirmed that high-risk HPV subtypes were detected in most cases but were not associated with recurrence.

Immunosuppression, expressed as low CD4+ T-cell count, is considered one of the most significant risk factors for disease recurrence in WLWH. Our

In our study, CD4+ T-cell count at the time of cervical treatment or at the time of the last control was not associated with a higher risk of recurrence. Literature data about the most appropriate prognostic CD4+ T-cell count are conflicting. Clifford et al. showed that nadir CD4+ T-cell count was a more discriminant measure of risk for CIN2+ than CD4+ T-cell count at diagnosis. Other studies found that CD4+ T-cell count at the time of treatment is a better predictor of persistent disease or recurrence than nadir CD4+ T-cell count. Our results could be interpreted as the fact that the pathogenesis of high-grade cervical lesions is multifactorial, and immunodeficiency could play a role as a cofactor, but not as a determining factor. Previous studies reporting this association may have been biased by not having evaluated HR-HPV positivity during follow up as a risk factor for recurrence.

The role of immunodeficiency in disease relapse could be a factor increasing the risk of acquiring and maintaining HR-HPV infection rather than in a direct role in the development of a new lesion. This finding is consistent with the existing literature suggesting that alterations in cell-mediated immune responses play a large role in the persistence of HPV infection.

FIGURE 1 Flowchart of study population
The use of HAART allows for prolonged suppression of HIV replication and improved immune status, as manifested in rising CD4 cell counts. It seems to be associated with a reduction of the incidence, progression, and recurrence of cervical lesions, especially if started at higher CD4+ T-cell count and used over longer durations by adherent patients. It could be speculated that HAART could be implicated in the effectiveness of the immune response in eliminating HPV infection immediately after the cervical treatment, preventing the persistence of subclinical infection and, therefore, the finding of an HR-HPV positivity during follow up. This effect could be in some way similar to the hypothesized mechanisms by which HPV vaccination before treatment could boost the immune response, keeping the virus under control and preventing it from reactivating. However, these mechanisms are still uncertain, and future studies are needed in this regard.

In the WLWH included in our cohort, HR-HPV test during follow up after cervical excisional treatment presented a high negative
predictive value (89.8%, 95% CI 80.6%–94.9%), allowing reassurance to negative patients about the low risk of recurrence, but the expected low positive predictive value (32.6%, 95% CI 27.8%–37.8%) implies the need for execution of further diagnostic tests (cervical cytology and colposcopy) to exclude disease recurrence.

Being HPV negative appears to be the most important protective factor against disease recurrence. HPV vaccination could therefore represent an additional protective factor after cervical excision, allowing a higher percentage of women to maintain the status of HPV negativity. HPV vaccination could also prevent new HPV infections, which in a long-term follow up could be confusing regarding the true incidence of high-grade disease persistence of new-onset cervical lesions. Future studies are undoubtedly needed regarding HPV vaccination after treatment in WLWH; at present, there are already ongoing study protocols for HPV vaccination after treatment in HIV-negative women. If this approach proves effective, it could be evaluated with further studies also in WLWH.

The increased risk of high-grade recurrence for patients aged 41 years or older that emerged from our data could be explained by the age-related immunosenescence of older WLWH that is reported to occur earlier than in HIV-negative women of the same age. Moreover, age has been reported as a risk factor for recurrence after cervical excision also in HIV-negative women, although it may be of less importance than other factors. In our study, we did not find any statistically significant association with sociodemographic characteristics (except age), procedural modalities, or margin involvement. It is interesting to note that smoking was not a risk factor for disease recurrence in our cohort, unlike what is reported in the literature. This lack of association could be related to the high percentage of smokers in our population (68.3%).

As also reported in a recent meta-analysis, HPV positivity during follow up seems to play a more important role than the positive margins in predicting disease recurrence. This may be even more relevant in a cohort of immunocompromised patients like WLHW, such as those included in our study.

The major strengths of our study are the large cohort of WLWH subjected to cervical treatment considered for the analysis, the extensive look at clinical data and pre/postoperative variables, the long-term follow up (up to 5 years from treatment for most patients), and its multicentric nature. Moreover, the outcome chosen in the study for recurrence (HSIL+) might have reduced the probability of detecting transient low-grade lesions. In addition, the long period of time covered by our study also allowed us to evaluate the potential effect of changes in ART, up to the current therapeutic regimens, that can provide longer lives for patients and reduce HIV transmission. The successes of ART have reduced HIV to a chronic condition in many parts of the world as progression to AIDS has become rare.

Limitations of our study include its retrospective nature, the absence of HPV genotyping, and the fact that HR-HPV testing was not performed in all the included women because it only entered clinical practice from 2002. In addition, it was not possible to discriminate if high-grade recurrence occurring many years after treatment could be the result of a new HR-HPV infection. However, the presented data about long-term follow up are necessary to deepen the history of these patients. Moreover, it also needs to be acknowledged that CD4 count at the time of treatment may not have the same clinical significance for each included WLWH, and generalization from these data may be limited from the heterogeneous immunologic management of the included women because of temporal changes in HAART use.

In conclusion, surgical excision of CIN seems to be an effective procedure in WLWH, with a high rate of negative follow up. However, a careful, intensive, and prolonged follow up after treatment is necessary. As the main risk factor for long-term recurrence seems to be HR-HPV positivity during follow up, the implementation of this test is needed in WLWH with a history of cervical excisional treatment with more systematic use of co-testing.
In our opinion, the interval of follow up after treatment could be individualized according to the patient’s age. Whereas in young women it is possible to adopt a follow-up interval similar to that used in HIV-negative women, older women should be followed at yearly intervals after 24 months from treatment.

CONFLICTS OF INTEREST
The authors have no conflicts of interest.

TABLE 2 Logrank test for factors associated with HR-HPV positivity during follow up in 271 women with diagnosis of CIN2/3 at the cone specimen

| Factor                                      | Population (n = 271) | Hazard ratio (95% CI) for HR-HPV positivity during follow up | P value |
|---------------------------------------------|----------------------|---------------------------------------------------------------|---------|
| Age, years                                  |                      |                                                              |         |
| ≤29                                         | 71 (26.2%)           | 1.48 (0.91–2.42)                                              | 0.073   |
| 30–35                                       | 81 (29.9%)           | 0.51 (0.33–0.79)                                              | 0.005   |
| 36–40                                       | 56 (20.7%)           | 0.90 (0.55–1.46)                                              | 0.658   |
| ≥41                                         | 63 (23.2%)           | 1.69 (0.95–3.00)                                              | 0.028   |
| First sexual intercourse ≤16 years          | 133 (49.1%)          | 1.32 (0.87–2.00)                                              | 0.180   |
| No. of partners five or fewer               | 125 (46.1%)          | 0.79 (0.52–1.20)                                              | 0.254   |
| Smoker                                      | 185 (68.3%)          | 1.64 (1.05–2.55)                                              | 0.043   |
| Nulliparous                                 | 135 (49.8%)          | 1.15 (0.76–1.74)                                              | 0.509   |
| Menopause                                   | 13 (4.8%)            | 1.31 (0.42–4.08)                                              | 0.589   |
| No ART at inclusion                         | 49 (18.1%)           | 1.14 (0.64–2.03)                                              | 0.642   |
| Pre-HAART at inclusion                      | 79 (29.2%)           | 0.67 (0.44–1.03)                                              | 0.068   |
| HAART at inclusion                          | 143 (52.7%)          | 1.33 (0.88–2.02)                                              | 0.159   |
| WHO Class                                   |                      |                                                              |         |
| “Severe” at inclusion                       | 62 (22.9%)           | 1.86 (1.04–3.33)                                              | 0.008   |
| “Advanced” at inclusion                     | 57 (21.0%)           | 1.16 (0.71–1.88)                                              | 0.534   |
| “Mild” at inclusion                         | 77 (28.4%)           | 0.80 (0.51–1.24)                                              | 0.320   |
| “Not significant” at inclusion              | 75 (27.7%)           | 0.66 (0.42–1.05)                                              | 0.100   |
| HR-HPV positivity at inclusion              | 113/126 (89.7%)      | 0.47 (0.09–2.44)                                              | 0.183   |
| LEEP                                        | 221 (81.6%)          | 0.97 (0.44–2.12)                                              | 0.935   |
| Laser                                       | 35 (12.9%)           | 1.34 (0.14–12.96)                                             | 0.769   |
| Cold knife                                  | 15 (5.5%)            | 0.99 (0.43–2.26)                                              | 0.984   |
| Positive endocervical margin                | 36 (13.3%)           | 1.05 (0.52–2.12)                                              | 0.890   |
| No ART at follow up                         | 30 (11.1%)           | 0.81 (0.40–1.65)                                              | 0.582   |
| Pre-HAART at follow up                      | 48 (17.7%)           | 1.43 (0.75–2.73)                                              | 0.208   |
| HAART at follow up                          | 193 (71.2%)          | 0.87 (0.52–1.44)                                              | 0.549   |
| WHO Class                                   |                      |                                                              |         |
| “Severe” at follow up                       | 62 (22.9%)           | 1.72 (0.98–3.02)                                              | 0.021   |
| “Advanced” at follow up                     | 42 (15.5%)           | 1.07 (0.61–1.89)                                              | 0.801   |
| “Mild” at follow up                         | 49 (18.1%)           | 1.28 (0.66–2.49)                                              | 0.417   |
| “Not significant” at follow up              | 118 (43.5%)          | 0.61 (0.40–0.93)                                              | 0.017   |

Abbreviations: ART, antiretroviral therapy; CIN, cervical intraepithelial neoplasia; HAART, highly active antiretroviral therapy; HR, high-risk; LEEP, loop electrical excision procedure.

Values are given as number (percentage) and hazard ratio (95% confidence interval).

HR-HPV was performed in 126 women at inclusion.

HR-HPV was performed in 148 women at follow up.

AUTHOR CONTRIBUTIONS
AA and CA contributed to the conception of the work; DCG, SF, GL, GB, SM, FMG, and PA contributed to the design of the work; DCG, SM, MM, DFA, FMM, and MC contributed to acquisition and analysis of data; AA, CA, DCG, and SF contributed to interpretation of data; DCG, SM, and GL drafted the work; AA and CA revised it critically for important intellectual content; all authors approved the final version to be published; and all authors agreed to be accountable for all.

In our opinion, the interval of follow up after treatment could be individualized according to the patient’s age. Whereas in young women it is possible to adopt a follow-up interval similar to that used in HIV-negative women, older women should be followed at yearly intervals after 24 months from treatment.
aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

REFERENCES
1. Vinodhini K, Shanmughapriya S, Das BC, Natarajaseenivasan K. Prevalence and risk factors of HPV infection among women from various provinces of the world. Arch Gynecol Obstet. 2012;285:771-777.
2. Massad LS, Xie X, Burk R, et al. Long-term cumulative detection of human papillomavirus among HIV seropositive women. AIDS. 2014;28:2601-2608.
3. Blitz S, Baxter J, Raboud J, et al. Evaluation of HIV and highly active antiretroviral therapy on the natural history of human papillomavirus infection and cervical cytopathologic findings in HIV-positive and high-risk HIV-negative women. J Infect Dis. 2013;208:454-462.
4. Lacey CJ. HPV vaccination in HIV infection. Papillomavirus Res. 2019;8:100174.
5. Kojic EM, Rana Al, Cu-Uvin S. Human papillomavirus vaccination in HIV-infected women: need for increased coverage. Expert Rev Vaccines. 2016;15:105-117.
6. Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2020;24:102-131.
7. Debeaudrap P, Sobngwi J, Tebeu PM, Clifford GM. Residual or recurrent precancerous lesions after treatment of cervical lesions in human immunodeficiency virus-infected women: a systematic review and meta-analysis of treatment failure. Clin Infect Dis. 2019;69:1555-1565.
8. Massad LS, Fazzari MJ, Anastos K, et al. Outcomes after treatment of cervical intraepithelial neoplasia among women with HIV. J Low Genit Tract Dis. 2007;11:90-97.
9. Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV). SICPCV Recommendations - Management of special cases [SICPCV website]. 2019. http://www.colposcopiaitaliana.it/pdf07/CAPITOLO_3_Raccomandazioni_SICPCV_Gestione_casi_particolari.pdf. Accessed December 19, 2020.
10. Arbyn M, Anttila A, Jordan J, et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition—summary document. Ann Oncol. 2010;21:448-458.
11. Arbyn M, Redman CWE, Verdoort F, et al. Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis. Lancet Oncol. 2017;18:1665-1679.
12. Mariani L, Sandri MT, Preti M, et al. HPV testing in follow-up of patients treated for CIN2+ lesions. J Cancer. 2016;7:107-114.
13. Nayar W, Wilbur DC. The Pap Test and Bethesda 2014. J Low Genit Tract Dis. 2015;19:271-281.
14. Bornstein J, Bentley J, Bösze P, et al. 2011 colposcopic terminology of the International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol. 2012;120:166-172.
15. Darragh TM, Colgan TJ, Cox JT, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med. 2012;136:1266-1297.
16. Centers for Disease Control and Prevention (CDC). Revised surveillance case definition for HIV infection - United States, 2014. Recommendations and Reports. 2014;63:1-10.
17. World Health Organization (WHO). WHO case definitions of HIV surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children [WHO website]. 2007. https://apps.who.int/iris/handle/10665/43699. Accessed December 19, 2020.
18. Lodhi CT, Michelin MA, Lima MI, et al. Factors associated with recurrence of cervical intraepithelial neoplasia after conization in HIV-infected and noninfected women. Arch Gynecol Obstet. 2011;284:191-197.
19. Clifford GM, Franceschi S, Keiser O, et al. Immunodeficiency and the risk of cervical intraepithelial neoplasia 2/3 and cervical cancer: a nested case-control study in the Swiss HIV cohort study. Int J Cancer. 2016;138:1732-1740.
20. Wright TC Jr, Koulos J, Schnoll F, et al. Cervical intraepithelial neoplasia in women infected with the human immunodeficiency virus: outcome after loop electrosurgical excision. Gynecol Oncol. 1994;55:253-258.
21. Kelly H, Weiss HA, Benavente Y, de Sanjose S, Mayaud P. Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis. Lancet HIV. 2018;5:e45-e58.
22. Sand FL, Kjaer SK, Frederiksen K, Dehlendorff C. Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status. Int J Cancer. 2019;147:641-647.
23. Ghelardi A, Parazzini F, Martella F, et al. SPERANZA project: HPV vaccination after treatment for CIN2. Gynecol Oncol. 2018;151:229-234.
24. Appay V, Sauce D. Assessing immune aging in HIV-infected patients. Virulence. 2017;8:529-538.
25. Fernández-Montoli ME, Tous S, Medina G, Castellarnau M, Garcia-Tejedor A, de Sanjosé S. Long-term predictors of residual or recurrent cervical intraepithelial neoplasia 2-3 after treatment with a large loop excision of the transformation zone: a retrospective study. BJOG. 2020;127:377-387.
26. Kemnic TR, Gulick PG. HIV Antiretroviral Therapy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. https://www.ncbi.nlm.nih.gov/books/NBK513308/. [Updated 2020 Jun 23].

How to cite this article: Agarossi A, Delli Carpini G, Sopracordevole F, et al. High-risk HPV positivity is a long-term risk factor for recurrence after cervical excision procedure in women living with HIV. Int J Gynecol Obstet. 2021:00–1–8. https://doi.org/10.1002/ijgo.13674